ERBB2 and breast carcinoma: Due to the success of the OlympiA trial, the National Comprehensive Cancer Network (NCCN) guidelines have been updated to acknowledge the role of gBRCA as a predictive biomarker and to recommend gBRCA testing to aid in treatment decisions with olaparib for patients with early-stage, high-risk, HER2- breast cancer [15].